Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 206-218

  Berger, Ariel ^a   Edelsberg, John ^a   Kallich, Joel ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

Author keywords

anemia; clinical practice patterns; darbepoetin alfa; epoetin alfa.; neoplasms

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BILLING AND CLAIMS; CANCER PATIENT; CLINICAL PRACTICE; COMORBIDITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE;

ADOLESCENT; ADULT; AGED; ANEMIA; COMORBIDITY; DATABASES, FACTUAL; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; UNITED STATES;

EID: 45249100648     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.004     Document Type: Article

References (20)

1. Aranesp (darbepoetin alfa) for injection [prescribing information]. http://www.aranesp.com/professional/cia/prescribing_information/prescrib ing_information.jsp. Accessed September 5, 2007.
2. Procrit [prescribing information]. http://www.procrit.com/common/prescribing_information/PROCRIT/PDF/Procri tBooklet.pdf Accessed September 5, 2007.
3. Waltzman R., Croot C., Justice G., et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 10 (2005) 642-650
4. Glaspy J., Vadhan-Raj S., Patel R., et al., for the 20030125 Study Group. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treat-ment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24 (2006) 2290-2297
5. Schwartzberg L., Yee L., Senecal F., et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 9 (2004) 696-707
6. Ross S., Allen I., Henry D., et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature [published correction appears in Clin Their. 2007;29:985-986]. Clin Ther 28 (2006) 801-831
7. Agency for Healthcare Research and Quality (AHRQ). Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment [AHRQ Web site]. http://effectivehealthcare.ahrq.gov/reports/topic.cfm?topic=2&sid=33 &rType=3. Accessed December 2006.
8. Rizzo J., Somerfield M., Hagerty K., et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. http://bloodjournal.hematologylibrary.org/cgi/reprint/blood-2007-08-1094 88v2. Accessed November 21, 2007.
9. Schwartzberg L., Shiffman R., Tomita D., et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Their 25 (2003) 2781-2796
10. Herrington J., Davidson S., Tomita D., et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 62 (2005) 54-62
11. Lefebvre P., Gosselin A., McKenzie R., et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 22 (2006) 1623-1631
12. Duan N. Smearing estimate: A nonparametric retransformation method. J Am Stat Assoc 78 (1983) 605-610
13. Mirtsching B., Charu V., Vadhan-Raj S., et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park) 16 Suppl 11 (2002) 31-36
14. Patton J., Reeves T., and Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9 (2004) 451-458
15. Chen E., Peake C., Buscaino E., et al. Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa (EPO)- and darbepoetin alfa (DARB)-treated cancer patients: Results of the dosing and outcomes study of erythropoiesis-stimulating therapies (D.O.S.E.) Registry. Presented at: American Society of Hematology (ASH) 48th Annual Meeting and Exposition (December 9-12, 2006) Orlando, Florida
16. Lefebvre P., Gosselin A., Fastenau J., et al. Treatment patterns and fre-quency of outpatient visits in adults with cancer receiving erythropoietic agents in a managed care organization. Presented at: Academy of Managed Care Pharmacy (AMCP) 17th Annual Meeting and Showcase (April 20-23, 2005) Denver, Colorado
17. Harris H., del Aguila M., Lopez J., et al. Anemia treatment costs in cancer patients treated with epoetin alfa or darbepoetin alfa in a managed care population. Presented at: Academy of Managed Care Pharmacy (AMCP) 2005 Educational Conference (October 5-8, 2005) Nashville, Tennessee
18. Charlson M., Pompei P., Ales K., and McKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
19. Fortner B., Tauer K., Zhu L., et al. The impact of medical visits for chemotherapy-induced anemia and neutropenia on the patient and care-giver: A national survey. Commun Oncol 1 (2004) 211-217
20. Houts A., Loh G., Fortner B., et al. Patient and caregiver time burden associated with anemia treat-ment in different patient populations. Support Care Cancer 14 (2006) 1195-1204